VERA in the 13F filings
Vera Therapeutics Inc · CUSIP 92337R101
- Quarter end
- 31 Dec 2024
- the date the book describes
- Filed
- 14 Feb 2025
- latest of these filings; the earliest 13 Feb 2025
- Managers listing it
- 4
- at least, of 95 tracked, among listed positions
- Comparable managers
- 94
- filed both Q3 2024 and Q4 2024; 4 listed it in both
- Shares listed
- 8,292,624
- combined, among listed positions
- Reported value
- $351m
- combined, at the quarter end
Among the 94 comparable managers: 3 buyers (opened or added shares) and 1 seller (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing VERA in Q4 2024
4 of 4 holders
| Action | Filing | |||||
|---|---|---|---|---|---|---|
| T. Rowe Price Associates Inc | 4,377,049 | $185m | under 0.1% | Added | +437,940 | 14 Feb 2025 (the filing on sec.gov) |
| Holocene Advisors LP | 1,875,963 | $79m | 0.25% | Trimmed | -78,565 | 14 Feb 2025 (the filing on sec.gov) |
| Woodline Partners LP | 1,202,466 | $51m | 0.34% | Added | +201,573 | 14 Feb 2025 (the filing on sec.gov) |
| Marshall Wace LLP | 837,146 | $35m | under 0.1% | Added | +253,421 | 13 Feb 2025 (the filing on sec.gov) |
Largest increases and reductions, by shares
Increases
- T. Rowe Price Associates Incexisting position · 4,377,049 shares now+437,940
- Marshall Wace LLPexisting position · 837,146 shares now+253,421
- Woodline Partners LPexisting position · 1,202,466 shares now+201,573
Reductions
- Holocene Advisors LPexisting position · 1,875,963 shares now-78,565
New positions and exits
New (0)
No new position among listed positions.
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q3 2022 | 1 | $3.6m | n.a. | n.a. |
| Q4 2022 | 3 | $7.8m | n.a. | n.a. |
| Q1 2023 | 1 | $14m | n.a. | n.a. |
| Q2 2023 | 2 | $28m | n.a. | n.a. |
| Q3 2023 | 1 | $35m | n.a. | n.a. |
| Q4 2023 | 1 | $39m | 0 | 1 |
| Q1 2024 | 6 | $185m | 5 | 1 |
| Q2 2024 | 5 | $257m | 4 | 1 |
| Q3 2024 | 6 | $346m | 5 | 1 |
| Q4 2024 | 4 | $351m | 3 | 1 |
| Q1 2025 | 2 | $77m | 1 | 1 |
| Q2 2025 | 2 | $68m | 2 | 0 |
| Q3 2025 | 3 | $71m | 2 | 1 |
| Q4 2025 | 4 | $481m | 17 | 9 |
| Q1 2026 | 6 | $299m | 18 | 10 |
| Q2 2026 | 1 | $43m | 8 | 18 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
VERA and LLY →VERA and JNJ →VERA and VRTX →Choose a stock to compare with VERA →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own VERA, latest filings →Back to the 13F Explorer →